Pretubulysin: a new option for the treatment of metastatic cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Nguyen DX, Bos PD, Massague J . Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9: 274–284.
Wyckoff JB, Jones JG, Condeelis JS, Segall JE . A critical step in metastasis: in vivo analysis of intravasation at the primary tumor. Cancer Res 2000; 60: 2504–2511.
Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2001; 61: 333–338.
Martin SS, Vuori K . Regulation of Bcl-2 proteins during anoikis and amorphosis. Biochim Biophys Acta 2004; 1692: 145–157.
Eckhardt BL, Francis PA, Parker BS, Anderson RL . Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012; 11: 479–497.
Newman DJ, Cragg GM . Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012; 75: 311–335.
Newman DJ, Cragg GM . Microbial antitumor drugs: natural products of microbial origin as anticancer agents. Curr Opin Invest Drugs 2009; 10: 1280–1296.
Li JW, Vederas JC . Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 161–165.
Danishefsky S . On the potential of natural products in the discovery of pharma leads: a case for reassessment. Nat Prod Rep 2010; 27: 1114–1116.
Wenzel SC, Muller R . Myxobacteria – ‘microbial factories' for the production of bioactive secondary metabolites. Mol Biosyst 2009; 5: 567–574.
Altmann KH, Memmert K . Epothilones as lead structures for new anticancer drugs – pharmacology, fermentation, and structure–activity-relationships. Prog Drug Res 2008; 66 273,275–334.
Sandmann A, Sasse F, Muller R . Identification and analysis of the core biosynthetic machinery of tubulysin, a potent cytotoxin with potential anticancer activity. Chem Biol 2004; 11: 1071–1079.
Pando O, Dorner S, Preusentanz R, Denkert A, Porzel A, Richter W et al. First total synthesis of tubulysin B. Org Lett 2009; 11: 5567–5569.
Shibue T, Hirai T, Okamoto I, Morita N, Masu H, Azumaya I et al. Total syntheses of tubulysins. Chemistry 2010; 16: 11678–11688.
Ullrich A, Chai Y, Pistorius D, Elnakady YA, Herrmann JE, Weissman KJ et al. Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis. Angew Chem Int Ed Engl 2009; 48: 4422–4425.
Herrmann J, Elnakady YA, Wiedmann RM, Ullrich A, Rohde M, Kazmaier U et al. Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy. PLoS One 2012; 7: e37416.
Eirich J, Burkhart JL, Ullrich A, Rudolf GC, Vollmar A, Zahler S et al. Pretubulysin derived probes as novel tools for monitoring the microtubule network via activity-based protein profiling and fluorescence microscopy. Mol Biosyst 2012; 8: 2067–2075.
Rath S, Liebl J, Furst R, Ullrich A, Burkhart JL, Kazmaier U et al. Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives. Br J Pharmacol 2012; 167: 1048–1061.
Kim SH, Ricci MS, El-Deiry WS . Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008; 68: 2062–2064.
Tao K, Fang M, Alroy J, Sahagian GG . Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008; 8: 228.
Cheng Y, Li G . Role of the ubiquitin ligase Fbw7 in cancer progression. Cancer Metast Rev 2012; 31: 75–87.
Inuzuka H, Fukushima H, Shaik S, Liu P, Lau AW, Wei W . Mcl-1 ubiquitination and destruction. Oncotarget 2011; 2: 239–244.
Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104–109.
Dumontet C, Jordan MA . Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9: 790–803.
Kavallaris M . Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194–204.
Jackson JR, Patrick DR, Dar MM, Huang PS . Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007; 7: 107–117.
Sasse F, Steinmetz H, Heil J, Höfle G, Reichenbach H . Tubulysins, new cytostatic peptides from myxobacteria acting on microtubuli. Production, isolation, physico-chemical and biological properties. J Antibiot (Tokyo) 2000; 53: 879–885.
Khalil MW, Sasse F, Lünsdorf H, Elnakady YA, Reichenbach H . Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. Chembiochem 2006; 7: 678–683.
Steinmetz H, Glaser N, Herdtweck E, Sasse F, Reichenbach H, Höfle G . Isolation, crystal and solution structure determination, and biosynthesis of tubulysins—powerful inhibitors of tubulin polymerization from myxobacteria. Angew Chem Int Ed Engl 2004; 43: 4888–4892.
den Hollander MW, Gietema JA, de Jong S, Walenkamp AM, Reyners AK, Oldenhuis CN et al. Translating TRAIL-receptor targeting agents to the clinic. Cancer Lett 2013; 332: 194–201.
Sánchez-Pérez T, Ortiz-Ferrón G, López-Rivas A . Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents. Cell Death Differ 2010; 17: 883–894.
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110–114.
Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways. J Biol Chem 1998; 273: 4928–4936.
Stone AA, Chambers TC . Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254: 110–119.
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139: 271–279.
Pfaffl MW . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.
Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L et al. Indirubin derivative 6BIO suppresses metastasis. Cancer Res 2013; 73: 6004–6012.